Access Pharmaceuticals initiates program applying Cobalamin platform to siRNA drug delivery

Technology is seen as providing missing link in commercial development of promising siRNA therapies

Dallas, TX, February 4, 2010

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP)announced today that it initiated an internal pre-licensing program to confirm the utility of its proprietary Cobalamin (vitamin B12) platform technology for targeted delivery of siRNA therapies. The program is considered important because, despite the widely publicized potential of RNA therapy, researchers up to now have been stymied in their efforts to design a pharmaceutical product that efficiently transports siRNA therapeutics into the cells they are designed to inhibit or kill.

Read more »

Cobalamin

Access Pharmaceuticals announces closing of $6.3 million in registered direct offering

Dallas, TX, February 2, 2010

ACCESS PHARMACEUTICALS, INC. (OTC Bulletin Board: ACCP), today announced that it closed its previously announced sale of approximately 2.10 million shares of its common stock and warrants to purchase approximately 1.05 million shares of its common stock for gross proceeds of approximately $6.3 million onJanuary 22, 2010.  Access sold the shares and warrants for $3.00per unit (each unit consisting of one share and a warrant to purchase 0.5 shares of common stock).  The exercise price of the warrants is $3.00 per share.

Read more »

Corporate

© Access Pharmaceuticals 2010 | Disclaimer